SCHEMBL2093768

SCHEMBL2093768

COc1cccc(C(O)c2cccc(OC)c2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AOC3 Q16853 3/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ CHRM2 P08172 1/20 0.51
▸ CHRM1 P11229 1/20 0.51
▸ CHRM3 P20309 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ BRD4 O60885 1/20 0.51
▸ ACHE P22303 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ TSHR P16473 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ CES2 O00748 1/20 0.48
▸ CES1 P23141 1/20 0.48
▸ ENPP2 Q13822 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27686957 0.94 AOC3 (0.54) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL477338 0.94 AOC3 (0.54) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL4822561 0.94 AOC3 (0.54) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL31067514 0.91 ALDH1A1 (0.66) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL17064808 0.91 ALDH1A1 (0.66) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL230701 0.89 NFE2L2 (0.51) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL3470936 0.89 AOC3 (0.50) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL18529828 0.89 AOC3 (0.50) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL31476413 0.89 AOC3 (0.50) AOC3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL23882848 0.88 ROCK1 (0.50) AOC3L3MBTL1PKMBRD4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 — — US disclosed
CN-112961183-B C3-phosphono substituted benzohydrofuran and benzofuran compounds and preparation method thereof 成都大学 2023-05-16 — — CN disclosed
CN-112961183-A C3-phosphono substituted benzohydrofurans and benzofuran compounds and processes for their preparation 成都大学 2021-06-15 — — CN disclosed
EP-3109703-B1 PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, AND METHOD FOR FORMING PATTERN USING SAME TOKYO ELECTRON LTD (JP) 2020-12-30 — — EP disclosed
US-20200375949-A1 BISPHENOL COMPOUNDS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-12-03 — — US disclosed
WO-2019104153-A1 BISPHENOL COMPOUNDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2019-05-31 — — WO disclosed
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting TOKYO ELECTRON LIMITED (JP) 2018-07-17 — — US disclosed
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting TOKYO ELECTRON LIMITED (JP) 2018-07-17 — — US disclosed
US-10018911-B2 Chemically amplified resist material and resist pattern-forming method JSR CORPORATION (JP) 2018-07-10 — — US disclosed
CN-101053558-A Diphenylethylene compounds and uses thereof CELGENE CORP (US) 2007-10-17 — — CN disclosed
US-20070185155-A1 Muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2007-08-09 — — US disclosed
EP-1799634-A2 DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2007-06-27 — — EP disclosed
EP-1603864-A4 DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF CELGENE CORP (US) 2007-04-11 — — EP disclosed
WO-2006026747-A2 DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2006-03-09 — — WO disclosed
EP-1603864-A2 DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2005-12-14 — — EP disclosed
US-20050107339-A1 Diphenylethylene compounds and uses thereof CELGENE CORPORATION 2005-05-19 — — US disclosed
US-20050014727-A1 Diphenylethylene compounds and uses thereof CELGENE CORPORATION 2005-01-20 — — US disclosed
WO-2004078144-A2 DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2004-09-16 — — WO disclosed
US-6440975-B1 Amino acid derivatives, the preparation and use thereof as endothelin antagonists ABBOTT LABORATORIES 2002-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107339-A1 Diphenylethylene compounds and uses thereof VHL, TNF, PTGES AOC3 1321/4885L3MBTL1 2413/4885CHRM2 4681/4885
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting ASIC1, ASIC3, CLTA AOC3 4095/4885L3MBTL1 3448/4885CHRM2 3722/4885
US-20200375949-A1 BISPHENOL COMPOUNDS RPP30, RPS10, RPS20 AOC3 3104/4885L3MBTL1 1338/4885CHRM2 4606/4885
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL AOC3 1996/4885L3MBTL1 613/4885CHRM2 3633/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL AOC3 1996/4885L3MBTL1 613/4885CHRM2 3633/4885
US-10018911-B2 Chemically amplified resist material and resist pattern-forming method SLC11A2, XRCC5, RAD54L AOC3 3396/4885L3MBTL1 4063/4885CHRM2 4183/4885
US-20050014727-A1 Diphenylethylene compounds and uses thereof VHL, TNF, PTGES AOC3 1321/4885L3MBTL1 2413/4885CHRM2 4681/4885
US-20070185155-A1 Muscarinic acetylcholine receptor antagonists CHRM3, CHRNG, CHRM2 AOC3 742/4885L3MBTL1 1742/4885CHRM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback